title: Targeting the ubiquitin proteasome pathway for the treatment of septic shock in patients.
abstract: Endotoxic shock is a serious systemic inflammatory response to an external biological stressor. The responsiveness of NF-kappaB is built upon rapid protein modification and degradation involving the ubiquitin proteasome pathway. Using transgenic mice, we have obtained in vivo evidence that interference with this pathway can alleviate the symptoms of toxic shock. We posit that administration of proteasome inhibitors may enhance the survival of patients with septic shock.
authors.affiliation: Ottawa Health Research Institute, Ottawa, ON, Canada K1Y 4E9. jzbrun@yahoo.com
authors.forename: Jan
authors.initials: J
authors.lastname: Brun
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Gray
mesh_terms: D000818:Animals; D051379:Mice; D008822:Mice, Transgenic; D009101:Multiple Myeloma / Q000503:physiopathology; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex / Q000187:drug effects*; D012772:Shock, Septic / Q000188:drug therapy* / Q000503:physiopathology; D015398:Signal Transduction; D025801:Ubiquitin / Q000187:drug effects*
chemical_list: D016328:NF-kappa B; D011480:Protease Inhibitors; D025801:Ubiquitin; D046988:Proteasome Endopeptidase Complex
references.citation: Neuropathol Appl Neurobiol. 2006 Feb;32(1):26-39
references.pmid: 16409551
references.citation: Biotechniques. 2001 Jul;31(1):120-6, 128, 130
references.pmid: 11464505
references.citation: Nat Cell Biol. 2005 Aug;7(8):758-65
references.pmid: 16056267
references.citation: Trends Immunol. 2006 Nov;27(11):533-40
references.pmid: 16982211
references.citation: Sci STKE. 2000 Nov 14;2000(58):pe1
references.pmid: 11752619
references.citation: Nature. 2001 Jul 19;412(6844):346-51
references.pmid: 11460167
references.citation: N Engl J Med. 1993 May 20;328(20):1471-7
references.pmid: 8479467
references.citation: Innate Immun. 2008 Oct;14(5):319-29
references.pmid: 18809656
references.citation: Nat Rev Immunol. 2002 Oct;2(10):725-34
references.pmid: 12360211
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3892-901
references.pmid: 17679727
references.citation: Cell. 2000 Oct 13;103(2):351-61
references.pmid: 11057907
references.citation: Genes Dev. 1999 Apr 15;13(8):1015-24
references.pmid: 10215628
references.citation: Mol Cell. 2004 Aug 27;15(4):535-48
references.pmid: 15327770
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9
references.pmid: 12391322
references.citation: Chest. 1991 Jan;99(1):169-75
references.pmid: 1984950
references.citation: J Immunol. 2002 Feb 1;168(3):1441-6
references.pmid: 11801687
references.citation: Nature. 2002 Dec 19-26;420(6917):885-91
references.pmid: 12490963
references.citation: J Biol Chem. 2002 May 10;277(19):16639-47
references.pmid: 11872748
references.citation: Br J Haematol. 2004 Oct;127(2):165-72
references.pmid: 15461622
references.citation: Genes Dev. 1995 Jul 1;9(13):1586-97
references.pmid: 7628694
references.citation: Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2683-8
references.pmid: 12766073
references.citation: Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11259-63
references.pmid: 7479976
references.citation: Shock. 2006 May;25(5):472-84
references.pmid: 16680012